Abstract
Despite the fact that neurons are rarely infected by the human immunodeficiency virus (HIV), neuronal loss is common in patients with HIV infection, likely due to the effects of viral proteins and inflammatory mediators on these cells. Despite the widespread use of highly active antiretroviral therapy (HAART), at least in developed nations, cognitive impairment and other neurological complications of HIV infection persist with devastating personal and socioeconomic consequences. Fortunately, we have made important advances in recent years in defining the molecular mechanisms by which HIV infection targets the nervous system for damage. Such understanding has opened numerous therapeutic options, which are only now beginning to be exploited. This review will highlight the current state of thought regarding the neuropathogenesis of HIV infection. It will summarize the most recent research looking at the roles of both viral and host factors in mediating HIV-induced neurological disease. Utilizing this knowledge base, a framework will be outlined for current and future therapeutic trials to prevent or improve neurological complications of HIV infection.
Keywords: HIV dementia, Tat, gp120, MMP, TNF, cytokines, blood brain barrier, HAART
Current Pharmaceutical Design
Title: Developments in HIV Neuropathogenesis
Volume: 12 Issue: 9
Author(s): Avindra Nath and Jeffrey A. Rumbaugh
Affiliation:
Keywords: HIV dementia, Tat, gp120, MMP, TNF, cytokines, blood brain barrier, HAART
Abstract: Despite the fact that neurons are rarely infected by the human immunodeficiency virus (HIV), neuronal loss is common in patients with HIV infection, likely due to the effects of viral proteins and inflammatory mediators on these cells. Despite the widespread use of highly active antiretroviral therapy (HAART), at least in developed nations, cognitive impairment and other neurological complications of HIV infection persist with devastating personal and socioeconomic consequences. Fortunately, we have made important advances in recent years in defining the molecular mechanisms by which HIV infection targets the nervous system for damage. Such understanding has opened numerous therapeutic options, which are only now beginning to be exploited. This review will highlight the current state of thought regarding the neuropathogenesis of HIV infection. It will summarize the most recent research looking at the roles of both viral and host factors in mediating HIV-induced neurological disease. Utilizing this knowledge base, a framework will be outlined for current and future therapeutic trials to prevent or improve neurological complications of HIV infection.
Export Options
About this article
Cite this article as:
Nath Avindra and Rumbaugh A. Jeffrey, Developments in HIV Neuropathogenesis, Current Pharmaceutical Design 2006; 12 (9) . https://dx.doi.org/10.2174/138161206776055877
DOI https://dx.doi.org/10.2174/138161206776055877 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets An Optimal Approach for Selecting Discriminant Regions for the Diagnosis of Alzheimer's Disease
Current Alzheimer Research Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Potential Enzymatic Targets in Alzheimer’s: A Comprehensive Review
Current Drug Targets Current Therapeutic Strategies and Future Perspectives for the Prevention of Arterial Thromboembolism: Focus on Atrial Fibrillation
Current Pharmaceutical Design Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Potentiality of Oxygen-Ozonetherapy to Improve the Health of Aging People
Current Aging Science Cutaneomeningospinal Angiomatosis (Cobb Syndrome) in a Young Patient
CNS & Neurological Disorders - Drug Targets Off-Label Trazodone Prescription: Evidence, Benefits and Risks
Current Pharmaceutical Design A Contemporary Approach to Macular Edema Treatment in Retinal Vein Occlusion
Vascular Disease Prevention (Discontinued) Therapeutic Perspectives in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) A Scientific Approach to Anti-Ageing Therapies: State of the Art
Current Pharmaceutical Design Cannabis Epidemiology: A Selective Review
Current Pharmaceutical Design Fenofibrate, Homocysteine and Renal Function
Current Vascular Pharmacology Radix Angelica Sinensis that Contains the Component Z-Ligustilide Promotes Adult Neurogenesis to Mediate Recovery from Cognitive Impairment
Current Neurovascular Research Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design Critical Review on the Chemical Aspects of Cannabidiol (CBD) and Harmonization of Computational Bioactivity Data
Current Medicinal Chemistry Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia
Current HIV Research An Overview of Non-Neural Sources of Calcitonin Gene-Related Peptide
Current Medicinal Chemistry